Pfizer Establishes Durham, North Carolina, Clinical Manufacturing Campus
12/23/2021
According to company officials, the facility will be responsible for the manufacturing and analytical release of clinical supplies for Pfizer’s gene therapy and biologics portfolio. Approximately 40 employees will relocate from the company’s Chapel Hill site.
The Durham facility is part of an $800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy research, development, and manufacturing.
“Gene therapy represents the next wave of innovation for patients living with rare diseases, for whom there are limited treatment options currently available,” said Paul Mensah, Vice President, BioTherapeutics Pharmaceutical Sciences at Pfizer. “Today represents the next step in strengthening Pfizer’s in-house gene therapy capabilities and underscores the unique ability, expertise, and resources we have to guide gene therapy through the entire development and manufacturing process and deliver this potentially life-changing technology to patients.”
Pfizer currently employs more than 3,600 people across its North Carolina sites, according to company officials. The new Durham location is an important part of Pfizer’s worldwide R&D network which includes locations in La Jolla, California; Boulder, Colorado; St Louis, Missouri; Pearl River, New York; Groton, Connecticut; and Cambridge and Andover, Massachusetts.
Project Announcements
Worksport Expands West Seneca, New York, Operations
05/10/2024
Clark Gas Co. Propane Cylinder Exchange Plans Thomasville, Alabama, Distribution Operations
05/10/2024
Columbia Vehicle Group Plans Aiken, South Carolina, Production Operations
05/09/2024
FIFCO USA Expands Rochester, New York, Genesee Brewery Operations
05/09/2024
Australia-Based Fortescue Establishes Buckeye, Arizona, Green Hydrogen Operations
05/09/2024
27North Expands Springfield, Missouri, Production Operations
05/09/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
Making Hybrid More Human in 2024
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
Last Word: Striking a Balance - Prioritizing Electric Infrastructure While Preparing for the Next Wave of Industrial Expansion
Q1 2024